Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a music and Brain-Training app boost reading in kids with dyslexia?

NCT ID NCT06592911

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested a digital app called Poppins Clinical in 306 children with dyslexia or other reading/writing learning disabilities. The app combines musical and cognitive exercises with reading training. One group used the app plus bi-monthly speech therapy, while the control group had weekly speech therapy alone. The goal was to see if the app could match standard therapy in improving reading skills.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Poppins Clinical (a digital app providing cognitive and musical training)
What this could lead to
If successful, this app could offer a convenient, at-home supplement to speech therapy, potentially reducing the need for frequent clinic visits while maintaining reading improvements.
What could go wrong
This is a non-inferiority trial, meaning it aims to show the app is not worse than standard care, not necessarily better. The study is completed but results are not yet widely available, so real-world benefits remain unconfirmed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

306 people

The number who actually took part.

Started

Dec 2024

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

7 to 11 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of SLD with reading deficit, based on a speech-language assessment. SLD with reading deficit is defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR, 2022). The speech-language assessment should consist of at least three reading and/or transcription tests with a SD (standard deviation) of at least - 1.4 or a result below the 20th percentile or two reading and/or transcription tests with a SD of at least - 2 SD or a results below the 10th percentile; * Subject aged between 7 and 11, enrolled from CE1 to CM2; * Subject receiving speech and reading therapy for less than 2 years, receiving speech and reading therapy for written language for less than 2 years, with a maximum treatment frequency of one session per week, either for at least 3 months for children followed for more than 3 months, or for the duration of the treatment for children followed for less than 3 months.; * French mother tongue or French bilingualism at home and more than 3 years schooling in France; * Tablet or smartphone available at home; * Subject affiliated to the French National Insurance (Sécurité Sociale); * Subject and parental/legal guardians consent to participate, and commitment to follow the protocol. Exclusion Criteria: * Subject has previously used Poppins Clinical or a previous version (Mila-Learn); * Unstabilized chronic illness (at investigator's discretion); * Participants with autism spectrum disorders or documented intellectual disabilities; * Vision or Hearing difficulties preventing the use of the tablet or smartphone; * Any condition that, in the opinion of the investigator, may prevent the patient from participating in the trial * Participant actively participating in an interventional study that may affect results. * Concurrent participation of any other family member in the same clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyslexia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Henri Laborit Poitiers, 86000

    Poitiers, 86000, France

  • Hôpital Pitié-Salpêtrière, Paris, Paris 75013

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.